Abstract
The gene-guided dosing strategy of warfarin generally leads to over-dose in patients at doses lower than 2 mg/kg, and only 50% of individual variability in daily stable doses can be explained. In this study, we developed a novel population pharmacokinetic (PK) model based on a warfarin dose algorithm for Han Chinese patients with valve replacement for improving the dose prediction accuracy, especially in patients with low doses. The individual pharmacokinetic (PK) parameter - apparent clearance of S- and R-warfarin (CLs) was obtained after establishing and validating the population PK model from 296 recruited patients with valve replacement. Then, the individual estimation of CLs, VKORC1 genotypes, the steady-state international normalized ratio (INR) values and age were used to describe the maintenance doses by multiple linear regression for 144 steady-state patients. The newly established dosing algorithm was then validated in an independent group of 42 patients and was compared with other dosing algorithms for the accuracy and precision of prediction. The final regression model developed was as follows: Dose=-0.023×AGE+1.834×VKORC1+0.952×INR+2.156×CLs (the target INR value ranges from 1.8 to 2.5). The validation of the algorithm in another group of 42 patients showed that the individual variation rate (71.6%) was higher than in the gene-guided dosing models. The over-estimation rate in patients with low doses (<2 mg/kg) was lower than the other dosing methods. This novel dosing algorithm based on a population PK model improves the predictive performance of the maintenance dose of warfarin, especially for low dose (<2 mg/d) patients.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745–51.
Shu WY, Li JL, Wang XD, Huang M . Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. Acta Pharmacol Sin 2015; 36: 535–43.
Singh O, Sandanaraj E, Subramanian K, Lee LH, Chowbay B . Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab Pharmacokinet 2011; 26: 130–6.
Ohno M, Yamamoto A, Ono A, Miura G, Funamoto M, Takemoto Y, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol 2009; 65: 1097–103.
Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, et al. Prospective study of warfarin in dose requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008; 84: 83–9.
Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009; 19: 226–34.
Miao L, Yang J, Huang C, Shen Z . Contribution of age, body weight and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Pharmacol 2007; 63: 1135–41.
Sasaki T, Tabuchi H, Higuchi S, Ieiri I . Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with forecasting. Pharmacogenomics 2009; 10: 1257–66.
Hamberg AK, Friberg LE, Hanséus K, Ekman-Joelsson BM, Sunnegårdh J, Jonzon A, et al. Warfarin dose prediction in children using pharmacometric bridging-comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol 2013; 12: 1275–83.
Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, et al. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thromb Haemost 2012; 107: 1083–91.
Hirsh J, Fuster V, Ansell J, Halperin JL . American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003; 41: 1633–52.
Hamberg AK, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther 2010; 87: 727–34.
Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol 2012; 73: 66–76.
Hamberg AK, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, et al. A PK-PD model for predicting the impact of age, CYP2C9 and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007; 81: 529–38.
Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L . Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn 2010; 37: 3–24.
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329–33.
Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101–10.
Peter S Craig, Michael Goldstein, Jonathan C Rougier, Allan H Seheult . Bayesian forecasting for complex systems using computer simulators. J Am Stat Assoc 2001; 96: 717–29.
Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 2015; 113: 1370–7.
Sangviroon A, Panomvana D, Tassaneeyakul W, Namchaisiri J . Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thaipatients taking warfarin. Drug Metab Pharmacokinet 2010; 25: 531–8.
Cai W, Jing H, Chen B, Shen Y, Lin S . Pharmacokinetics of warfarin enantiomers in patients with cardiac valve replacement. Chin Pharm J 1997; 32: 152–4.
Liu Y, Yang J, Xu Q, Xu B, Gao L, Zhang Y, et al. Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients. Thromb Res 2012; 130: 435–40.
Acknowledgements
We thank all of the clinicians, nurses and patients who participated in this study. This study was supported by the Department of Cardiovascular, Nanjing First Hospital, Nanjing Medical University. In addition, the authors wish to thank Prof Li-yan MIAO from the First Hospital Affiliated to Soochow University for her assistance with data support. The research was supported by the Science and Technology Program of Nanjing, China (No 2014sc517048).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zhu, Yb., Hong, Xh., Wei, M. et al. Development of a novel individualized warfarin dose algorithm based on a population pharmacokinetic model with improved prediction accuracy for Chinese patients after heart valve replacement. Acta Pharmacol Sin 38, 434–442 (2017). https://doi.org/10.1038/aps.2016.163
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2016.163
Keywords
This article is cited by
-
Construction of warfarin population pharmacokinetics and pharmacodynamics model in Han population based on Bayesian method
Scientific Reports (2024)
-
Association between gene polymorphisms and initial warfarin therapy in patients after heart valve surgery
Pharmacological Reports (2024)
-
Developing Chinese race-specific warfarin dose prediction algorithms
International Journal of Clinical Pharmacy (2023)
